Clinical trials: Mixed Hyperlipidemia
Primary Hyperlipidemia and Mixed Dyslipidemia
Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody
This is a randomized, double-blind, placebo-controlled trial to evaluate the effect of evolocumab, atorvastatin, and combination therapy on lipoprotein kinetics.
- Trial name
- FLOREY (NCT02189837)
- Testing
- Evolocumab, Atorvastatin
- Where
- 2 sites in Australia
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Amgen
Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events
Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk
The primary objective of the study was to evaluate the effect of 12 weeks of subcutaneous evolocumab administered every 2 weeks and once a month, compared with placebo, on percent change from baseline in LDL-C when used in…
- Trial name
- AMG145 (NCT01953328)
- Testing
- Atorvastatin, Evolocumab
- Where
- 54 sites in Japan
- Volunteers
- 409 people
- Sponsor
- Amgen
Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of SAL003 in Combination With Statin Therapy in Patients With Hypercholesterolemia and Mixed Dyslipidemia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of Recombinant Fully Human Anti-PCSK9 Monoclonal Antibody Injection (SAL003) in Combination with Statin…
- Trial name
- NCT07253584
- Testing
- SAL003 140 mg
- Where
- China
- Volunteers
- 720 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Hypercholesterolaemia, Mixed Dyslipidaemia
Single Dose Oral Bioequivalence Study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated Tablets in Healthy Adult Human Subjects Under Fasting Conditions.
Single dose oral bioequivalence study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated tablets in healthy adult human subjects under fasting conditions.
- Conditions
- Hypercholesterolaemia, Mixed Dyslipidaemia, Cardiovascular Diseases
- Trial name
- NCT06923956
- Testing
- Bempedoic Acid Film Coated Tablet, Nilemdo® (Bempedoic Acid) Film-coated tablets
- Where
- India
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Primary Hypercholesterolemia
DNV001 Injection in Patients With Hypercholesterolemia
This is a Phase II clinical study to evaluate the effectiveness and safety of different doses of DNV001 injection in patients with primary hypercholesterolemia or mixed dyslipidemia who have not achieved adequate control of…
- Trial name
- DNV001 (NCT07391722)
- Testing
- DNV001 Injection
- Volunteers
- 120 people
- Sponsor
- Hangzhou Dinovate Biotech Co., Ltd
Primary Hypercholesterolemia, Mixed Hyperlipemia
Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage
The study is ongoing to evaluate the efficacy and safety of SHR-1209 in patients with hypercholesterolemia and hyperlipemia.
- Trial name
- NCT04849000
- Testing
- SHR-1209
- Where
- China
- Volunteers
- 709 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Hyperlipidemia, Hypercholesterolemia
A Study to Evaluate an Investigational Drug in Patients With Mixed Hyperlipidemia (0653A-071)(COMPLETED)
The purpose of this study is to assess the cholesterol lowering effects of an investigational drug in patients with mixed hyperlipidemia (high cholesterol and high triglycerides).
- Conditions
- Hyperlipidemia, Hypercholesterolemia, Hypertriglyceridemia
- Trial name
- NCT00093899
- Testing
- ezetimibe (+) simvastatin
- Volunteers
- 611 people
- Sponsor
- Organon and Co
Hyperlipidemia, Dyslipidemia
Efficacy & Long-term Safety Comparison Study of NK-104-CR & Livalo® IR With Primary Hyperlipidemia or Mixed Dyslipidemia
The purpose of this study is to demonstrate the superior efficacy of NK-104-CR 8 mg daily compared to Livalo® IR 4 mg daily on fasting serum low-density lipoprotein cholesterol (LDL-C) reduction and to evaluate the comparative…
- Trial name
- NCT02799758
- Testing
- NK-104-CR, Livalo® IR
- Where
- 69 sites in United States
- Sponsor
- Kowa Research Institute, Inc.
Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on a Background of Lipid-lowering Therapy
The purpose of this study is to compare the effectiveness, safety of SYH2053 in participants with primary hypercholesterolemia (non-familial) or mixed dyslipidemia on a background of lipid-lowering therapy.
- Trial name
- NCT07421284
- Where
- China
- Volunteers
- 900 people
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Hypercholesterolemia, Hyperlipidemia
Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)
This is a 16-week clinical trial in lipid clinic patients for whom niacin therapy is appropriate to evaluate the tolerability of MK0524A versus niacin extended-release.
- Trial name
- NCT00378833
- Testing
- niacin (+) laropiprant, niacin
- Volunteers
- 1,300 people
- Sponsor
- Merck Sharp & Dohme LLC
Primary Hypercholesterolemia, Mixed Hyperlipidemia
Lipid Efficacy Study (0524B-022)(COMPLETED)
This is a 12-week clinical trial in patients with primary hypercholesterolemia or mixed hyperlipidemia, studying the effects of coadministered MK0524B on lipids. There will be 6 scheduled clinic visits, and 7 treatment arms.
- Trial name
- NCT00269217
- Testing
- niacin (+) laropiprant (+) simvastatin, Comparator: niacin (+) laropiprant, Comparator: simvastatin
- Volunteers
- 1,400 people
- Sponsor
- Merck Sharp & Dohme LLC
Coronary Atherosclerosis, Mixed Dyslipidemia
A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events
The overall objective of the trial is to evaluate the effect of the triple therapy consisting of bempedoic acid (BA), ezetimibe (EZE), and high-intensity atorvastatin or rosuvastatin on changes in coronary plaque burden and…
- Conditions
- Coronary Atherosclerosis, Mixed Dyslipidemia, Hypercholesterolemia
- Trial name
- NCT07474649
- Testing
- Bempedoic acid, Ezetimibe, Rosuvastatin
- Where
- 12 sites in Germany, Italy and 1 more
- Volunteers
- 103 people
- Sponsor
- Daiichi Sankyo
Primary Hypercholesterolaemia, Mixed Hyperlipidaemia
Lipid Efficacy/Tolerability Study (0524A-020)
A 28-week clinical trial in patients with primary hypercholesterolemia or mixed hyperlipidemia to study the effects of MK0524A on lipids and tolerability. There will be 9 scheduled clinic visits, and 3 treatment groups.
- Trial name
- NCT00269204
- Testing
- niacin (+) laropiprant, ER-niacin
- Volunteers
- 1,620 people
- Sponsor
- Merck Sharp & Dohme LLC
Hyperlipidemia
Comparison of the Combination of Fenofibrate and Simvastatin Versus Atorvastatin
Mixed or combined hyperlipidemia is a common metabolic disorder characterized by both hypercholesterolemia and hypertriglyceridemia.
- Trial name
- NCT00362934
- Testing
- fenofibrate / simvastatin, Atorvastatin
- Where
- 68 sites in Bulgaria, Czechia and 3 more
- Volunteers
- 516 people
- Sponsor
- Solvay Pharmaceuticals
Primary Hypercholesterolemia or Mixed Hyperlipidemia
QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated Low Density Lipoprotein Cholesterol (LDL-C)
To evaluate the efficacy, safety and immunogenicity of QCL7401 subcutaneous administration in patients with primary hypercholesterolemia or mixed hyperlipidemia with poorly controlled LDL-C elevated on optimized lipid-lowering…
- Trial name
- NCT07441317
- Testing
- QLC7401
- Volunteers
- 780 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Hyperlipidemia
Comparison of the Combination of Fenofibrate and 20 mg Simvastatin Versus 40 mg Simvastatin Monotherapy
Mixed or combined hyperlipidemia is a common metabolic disorder characterized by both hypercholesterolemia and hypertriglyceridemia.
- Trial name
- NCT00349375
- Testing
- Fenofibrate/Simvastatin, Simvastatin
- Where
- 110 sites in Czechia, Denmark and 6 more
- Volunteers
- 1,040 people
- Sponsor
- Solvay Pharmaceuticals
Primary Hypercholesterolemia, Mixed Hyperlipidemia
A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)
This is a 3-period study. Periods 1 and 2 will evaluate the effects of multiple doses of laropiprant on the antiplatelet effects of clopidogrel and aspirin administered in combination in participants with primary…
- Trial name
- NCT01012219
- Testing
- niacin (+) laropiprant, Comparator: aspirin, Comparator: clopidogrel
- Volunteers
- 36 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypercholesteremia, Hyperlipidemia
Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)
This is a 12-week clinical trial in lipid clinic patients for whom niacin therapy is appropriate to evaluate the efficacy of MK0524 to improve the tolerability of extended-release niacin.
- Trial name
- NCT00376584
- Testing
- MK-0524A, ER Niacin
- Volunteers
- 825 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypercholesterolemia, Mixed Dyslipidemia
SurveY Followed by a Retrospective Chart Review to Describe the Key Factors Leading to Physician's Decision to Treat Patients at High and Very High Cardiovascular Risk With hyperchOlesterolemia or Mixed Dyslipidemia With NUSTENDI®
In this study, a survey of office-based cardiologists and lipid management specialists will be conducted on treatment decisions for NUSTENDI® (bempedoic acid 180 mg fixed dose combination [FDC] with ezetimibe 10 mg) followed by a…
- Trial name
- NCT05546398
- Testing
- Bempedoic Acid 180Mg/Ezetimibe 10Mg Tab, No study drug
- Where
- 63 sites in Germany
- Volunteers
- 500 people
- Sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Non-familial Hypercholesterolemia, Mixed Hyperlipidemia
Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in Patients With Hypercholesterolemia
To evaluate the efficacy, safety, pharmacokinetics and immunogenicity of SHR-1209 subcutaneous administration in patients with non-familial hypercholesterolemia and mixed hyperlipidemia after lipid-lowering therapy
- Trial name
- NCT04885218
- Where
- China
- Volunteers
- 692 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.